HiCisco (002653.SZ): Clinical trial application for new indications of HSK44459 tablets approved

Zhitong Finance App News, HiCisco (002653.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. After review, the HSK44459 clinical trial application for new indications accepted in October 2025 met the relevant requirements for drug registration and agreed to carry out clinical trials with this product.

HSK44459 tablets are a new drug independently developed by the company to treat inflammatory bowel diseases (including ulcerative colitis and Crohn's disease) with independent intellectual property rights. Preclinical research results show that this product has clear targets, accurate curative effects, and good safety. It is a small-molecule drug with great potential for development. It has a high benefit/risk ratio for clinical application, and has broad clinical application prospects. It is expected to become an effective treatment for inflammatory bowel disease (including ulcerative colitis and Crohn's disease), solving the current problem of lack of clinical medication.